The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.
 
Matthew Ingham
Consulting or Advisory Role - Apexigen; Daiichi Sankyo; Xencor
Research Funding - Apexigen (Inst); Mirati Therapeutics (Inst); PTC Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech
 
Jacob B. Allred
No Relationships to Disclose
 
Katherine Gano
No Relationships to Disclose
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Consulting or Advisory Role - Bayer; Blueprint Medicines; Daiichi; deciphera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); Merck (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice
 
Steven Attia
Research Funding - AB Science (Inst); Adaptimmune (Inst); Advenchen Laboratories (Inst); Bavarian Nordic (Inst); Bayer (Inst); Blueprint Medicines (Inst); BTG (Inst); CBA Pharma (Inst); Deciphera (Inst); Desmoid Tumor Research Foundation; Epizyme (Inst); FORMA Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gradalis (Inst); Immune Design (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Melissa Amber Burgess
Consulting or Advisory Role - EMD Serono
Research Funding - Merck
Travel, Accommodations, Expenses - SpringWorks Therapeutics
(OPTIONAL) Uncompensated Relationships - TRACON Pharma
 
Mahesh Seetharam
Stock and Other Ownership Interests - BioNTech; crispr therapeutics; Inovio Pharmaceuticals; Johnson & Johnson/Janssen; Moderna Therapeutics; Pfizer
Honoraria - Daiichi Sankyo; Horizon CME
 
Sosipatros Alexandros Boikos
No Relationships to Disclose
 
Nam Bui
Consulting or Advisory Role - NewBay Pharma
 
James Lin Chen
Consulting or Advisory Role - Syapse
Speakers' Bureau - Foundation Medicine
Research Funding - Eisai
Patents, Royalties, Other Intellectual Property - MatchTX
 
Julia Lee Close
No Relationships to Disclose
 
Gregory Michael Cote
Consulting or Advisory Role - C4 Therapeutics; Epizyme; PharmaMar
Research Funding - Agios (Inst); Bavarian Nordic; Bayer (Inst); Boston Biomedical (Inst); CBA Research (Inst); Eisai (Inst); Epizyme (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Plexxikon (Inst); Springworks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Premal H. Thaker
Stock and Other Ownership Interests - Celsion
Consulting or Advisory Role - Aravive; Celsion; Iovance Biotherapeutics; Novocure; Stryker; Tesaro
Speakers' Bureau - AstraZeneca; Merck; Tesaro
Research Funding - GlaxoSmithKline (Inst); Merck (Inst)
 
S. Percy Ivy
No Relationships to Disclose
 
Biswajit Das
Research Funding - Illumina (Inst)
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; CytomX Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology; Syros Pharmaceuticals; Zentalis
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology
 
Bose Kochupurakkal
No Relationships to Disclose
 
Jane B. Trepel
Research Funding - AstraZeneca (Inst); EpicentRX (Inst); Syndax (Inst)
 
Yves Pommier
Research Funding - AstraZeneca (Inst); EMD Serono/Merck (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Tarveda Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Y. Pommier is an inventor and holds NIH patents for the non-camptothecin topoisomerase I inhibitors LMP400 (indotecan), LMP744, and LMP776 (indimitecan).
 
Gary K. Schwartz
Stock and Other Ownership Interests - Abbott; Abbvie; Becton Dickinson; Bristol-Myers Squibb; GlaxoSmithKline; JOHNSON AND JOHNSON COM; Merck; Pfizer
Consulting or Advisory Role - Array BioPharma; Array BioPharma; Bayer; Bionaut Labs; Daiichi Sankyo; Ellipses Pharma; Epizyme; Fortress Biotech; Gencirq; Iovance Biotherapeutics; Pfizer; PTC Therapeutics; PureTech
Research Funding - Astex Pharmaceuticals; Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Array BioPharma; Daiichi Sankyo; Epizyme; Epizyme; Iovance Biotherapeutics; PTC Therapeutics; PureTech